Actively Recruiting
Phase 1 Study of MIL97 Drug to Test Safety and Effectiveness in Adults With Advanced or Metastatic Solid Tumors
Led by Beijing Mabworks Biotech Co., Ltd. · Updated on 2024-03-13
62
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying MIL97 in a Phase 1, global, multi-center, open-label trial to assess its safety, tolerability, pharmacokinetics, biomarkers, and efficacy in adults with advanced or metastatic solid tumors. This first-in-human study includes a dose escalation phase to determine safe dosing levels followed by a dose expansion phase to further explore dosing and treatment effects. The study uses an accelerated titration design initially, then a 33 dose-escalation design, aiming to find appropriate doses for further testing. Participants receive intravenous infusions of MIL97 at varying doses starting at 0.01 mgkg every three weeks, with dose escalation through several cohorts up to 0.45 mgkg. After initial dose escalation, one or two dosing schedules every two or three weeks will be selected for dose expansion, including 10 subjects per cohort. Each infusion lasts 60 to 90 minutes and is given on Day 1 of each treatment cycle. During the study, participants will have regular assessments to monitor safety, side effects, and treatment effects. Researchers will track adverse events, pharmacokinetics, and tumor response over up to 2.5 years, including measures like objective response rate, progression-free survival, and overall survival. Biomarker and immunogenicity analyses will also be conducted. Participants will be followed closely during treatment and after to evaluate long-term outcomes.
CONDITIONS
Brief Title
Treatment of Advanced and Metastatic Solid Tumors With MIL97
Research Team
J
Jianming Xu, Ph.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here